<DOC>
	<DOCNO>NCT01767519</DOCNO>
	<brief_summary>A study evaluate efficacy safety BOTOX® Solifenacin patient overactive bladder ( OAB ) urinary incontinence .</brief_summary>
	<brief_title>A Study Evaluating Efficacy Safety BOTOX® Solifenacin Patients With Overactive Bladder Urinary Incontinence</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Symptoms Overactive Bladder ( OAB ) ( frequency/urgency ) urinary incontinence least 6 month Inadequate response limit side effect anticholinergic treatment OAB Overactive Bladder cause neurological condition Patient predominance stress incontinence Use anticholinergic medication treat OAB symptom 7 day prior screen Previous use solifenacin History evidence pelvic urological abnormality Previous use botulinum toxin serotype urological condition Previous use botulinum toxin serotype nonurological condition within 12 week randomization Diagnosis Myasthenia gravis , EatonLambert Syndrome , Amyotrophic Lateral Sclerosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>